Prostate Cancer Survivorship Essentials for Men with Prostate Cancer on Androgen Deprivation Therapy (ADT) (PCEssentials Hormone Therapy Study)

Not Applicable

Recruiting

• Conditions: Androgen Deprivation Therapy in Prostate Cancer; Cancer - Prostate

• Registration Number: ACTRN12622000025730
• Lead Sponsor: niversity of Southern Queensland

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2022-01-13
• Last Update Posted: 12 December 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: Male
• Target Recruitment: 236

Inclusion Criteria

Men who: i) have been diagnosed with prostate cancer and be commencing, or within 3
months of commencement of, ADT, and expected (based on clinical information) to be on
ADT for a minimum continuous time period of 12 months; ii) are able to read and speak
English; iii) are able to give written informed consent; iv) have no previous history of head injury, dementia or psychiatric illness; v) have no other concurrent cancer; and vi) have
phone access.

Exclusion Criteria

Men with castrate resistant and confirmed metastatic disease will be excluded on the
basis of having progressive and incurable disease that may rapidly progress. No other
disease stage criteria will be applied as the focus of this study is the amelioration of side
effects of androgen deprivation therapy in the short (3 months) and medium-long (12
months post ADT commencement) term.

Study & Design

• Study Type: Interventional
• Study Design: Not specified